1 / 5

Efficacy of Ombitasvir/Paritaprevir/Ritonavir/Dasabuvir/RBV for Genotype 1 Patients on Opioid Replacement Therapy

Study on the effectiveness of ombitasvir/paritaprevir/ritonavir/dasabuvir/ribavirin for genotype 1 HCV patients on opioid replacement therapy. Results show high SVR12 rates with well-tolerated regimen and minimal adverse events.

albertbell
Download Presentation

Efficacy of Ombitasvir/Paritaprevir/Ritonavir/Dasabuvir/RBV for Genotype 1 Patients on Opioid Replacement Therapy

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. M14-103 Study: ombitasvir/paritaprevir/ritonavir + dasabuvir + RBV for genotype 1 on opioid replacement therapy • Design Open-label W12 W24 18-70 years HCV genotype 1 HCV RNA > 10,000 IU/ml Naïve or pre-treated with PEG-IFN + RBV No cirrhosis ≥ 6 months opioid replacement* No HBV or HIV co-infection N = 38 SVR12 * Methadone or buprenorphine (± naloxone) • Treatment regimens • Co-formulated ombitasvir (OBV)/paritaprevir (PTV)/rironavir (r) : 25/150/100 mg QD = 2 tablets • Dasabuvir(DSV) : 250 mg BID • RBV : 1000 or 1200 mg/day (bid dosing) according to body weight (< or ≥ 75 kg) • Objective • Primary endpoint : SVR12 (HCV RNA < 25 IU/ml), with 95% CI • Intensive 24 hours steady-state PK analysis Lalezari J. J Hepatology2015;63:364-9 M14-103

  2. M14-103 Study: ombitasvir/paritaprevir/ritonavir + dasabuvir + RBV for genotype 1 on opioid replacement therapy Baseline characteristics and outcome No virologic breakthrough, no relapse Lalezari J. J Hepatology2015;63:364-9 M14-103

  3. M14-103 Study: ombitasvir/paritaprevir/ritonavir + dasabuvir + RBV for genotype 1 on opioid replacement therapy Adverse events, n (%) Lalezari J. J Hepatology2015;63:364-9 M14-103

  4. M14-103 Study: ombitasvir/paritaprevir/ritonavir + dasabuvir + RBV for genotype 1 on opioid replacement therapy Steady-stade pharmacokinetic parameters (N = 22) • The steady-state exposures for OBV, PTV, and RTV were comparable to exposures in phase I studies of adults receiving similar formulations of OBV/PTV/r + DSV without methadone or buprenorphine, while exposures of DSV and DSV M1 were slightly lower * Median (arithmetic mean ± SD) ; ** AUC24 for drugs qd, AUC12 for drugs BID Lalezari J. J Hepatology2015;63:364-9 M14-103

  5. M14-103 Study: ombitasvir/paritaprevir/ritonavir + dasabuvir + RBV for genotype 1 on opioid replacement therapy • Summary • The 3D + RBV regimen achieved an SVR12rate of 97.4% among these 38 genotype 1-infected patients receiving opioid replacement therapy • No viral breakthroughs or relapses were observed • The regimen was well tolerated, with low rate of discontinuation • Adverse events were generally mild • Drug-drug interactions did not impact HCV treatment or opioid maintenance • No patient required a change in the dosage of methadone or buprenorphine during study treatment • 12 weeks all-oral regimen of OBV/PTV/r + DSV + RBV is well-tolerated and may be an attractive treatment option for genotype 1 infected patients receiving opioid replacement therapy Lalezari J. J Hepatology2015;63:364-9 M14-103

More Related